Gene

DLL3

delta like canonical Notch ligand 3

Explore in graph →CI-GENE-00043469HGNC:2909 ENSG00000090932 NCBI 10683 CIViC Approved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DLL3 Expression2
Rovalpituzumab Tesirine	Lung Small Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	4	submitted	EID7764 In a phase II trial, patients with DLL3-expressing small cell lung carcinoma were treated with rovalpituzumab tesirine. Only patients with 1% or more tumor cells expressing DLL3 were enrolled. In this… (full text at CIViC) PMID 31506387 · Morgensztern et al., 2019 · Open in CIViC	civic
〃	Lung Small Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID5919 74 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma received at least one dose of rovalpituzumab tesirine in a phase 1 trial. 11 (18%) of 60 assessable patients … (full text at CIViC) PMID 27932068 · Rudin et al., 2017 ·

Cohorts

Alteration frequency by cohort (2)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved2 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Non-Small Cell Lung Cancer (MSK, Science 2015) nsclc_mskcc_2015	Lung Non-Small Cell Carcinoma	Ssm	3	16

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.